-+ 0.00%
-+ 0.00%
-+ 0.00%

Upstream Bio says Phase 2 VALIANT trial shows verekitug cuts severe asthma exacerbation rate 56%

PUBT·09/08/2026 07:30:15
Listen to the news
Upstream Bio says Phase 2 VALIANT trial shows verekitug cuts severe asthma exacerbation rate 56%
  • Upstream Bio presented Phase 2 VALIANT trial results for verekitug in severe asthma in an oral session at ERS Congress 2026.
  • Study showed fewer asthma flare-ups versus placebo, with improvements in breathing measures and airway inflammation indicators.
  • Safety profile remained favorable, with no meaningful impact from immunogenicity on safety or efficacy.
  • Phase 3 trials in severe asthma and CRSwNP remain slated to start in Q1 2027, testing a 400 mg quarterly regimen.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080330PRIMZONEFULLFEED9822553) on September 08, 2026, and is solely responsible for the information contained therein.